Current Developments in Needle-Free Vaccine Delivery
Presented by Heather Callender-Potters, Co-Chairman & Global Business Development Officer, PharmaJet
This presentation provided an opportunity for our Coalition to learn about developments and current experiences with needle-free vaccine delivery.
Based in Golden, Colorado, PharmaJet is a medical device company dedicated to the development of needle-free injection technology, with the goal of reducing the use of needles in healthcare settings around the world. Their Jet Injector device recently received U.S. FDA 510(k) marketing clearance and delivers liquid vaccines intramuscularly or subcutaneously by means of a narrow, precise fluid stream.
Presentation topics included:
- History of jet injection vaccine administration technology
- Importance of needle-free vaccine delivery
- Needle-Free Injector Product overview and benefits
- Efficacy of needle-free vaccine delivery (including related research study results)
- Regulatory overview and FDA approval
- Post-marketing evaluation-the experience so far
- What's next? Future of needle-free vaccine delivery
About the Presenter:
Heather Callender-Potters
Co-Chairman & Global Business Development Officer
Ms. Callender-Potters has a Bachelor of Arts degree in International Management from Claremont McKenna College and an MBA from Wharton, the University of Pennsylvania. One of the co-founders of PharmaJet, Heather has 23 years of Private Equity fund management and international investment (BCEE; Enterprise Investors) across multiple jurisdictions, and has managed individual investments and financial investor consortiums, ranging from $1 million to an excess of $100 million. She has also held board positions with several companies across a variety of industries ranging from auto-parts, to systems integration, publishing, and light-manufacturing.
PharmaJet-Flu-for-Pharmacy-Public-Health-and-Hospital-Immunization-CCI-Jan-2015-short
